Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q17019665> ?p ?o }
Showing triples 1 to 34 of
34
with 100 triples per page.
- Q17019665 subject Q6403530.
- Q17019665 abstract "Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development and commercialisation of innovative gene-based medicines. It was established in 1995 as a spin out from Oxford University. The lead product is TroVax, a therapeutic cancer vaccine for multiple solid cancers, which is in Phase III development incollaboration with Sanofi-Aventis. TroVax failed in a key kidney cancer test in 2008 which caused a dramatic drop in Oxford BioMedica's share priceThe Company’s advanced development pipeline includes treatments for cancer, Parkinson's disease and retinopathy. The company's early stage development pipeline includes preclinical candidates for Stargardt disease, motor neuron disease, spinal muscular atrophy and AIDS.".
- Q17019665 foundingYear "1995".
- Q17019665 industry Q507443.
- Q17019665 numberOfEmployees "72".
- Q17019665 revenue "1500000.0".
- Q17019665 wikiPageExternalLink www.oxfordbiomedica.co.uk.
- Q17019665 wikiPageWikiLink Q11085.
- Q17019665 wikiPageWikiLink Q11707850.
- Q17019665 wikiPageWikiLink Q1317319.
- Q17019665 wikiPageWikiLink Q158205.
- Q17019665 wikiPageWikiLink Q507443.
- Q17019665 wikiPageWikiLink Q550455.
- Q17019665 wikiPageWikiLink Q580290.
- Q17019665 wikiPageWikiLink Q6403530.
- Q17019665 wikiPageWikiLink Q7844782.
- Q17019665 foundation "1995".
- Q17019665 industry Q507443.
- Q17019665 name "Oxford BioMedica plc".
- Q17019665 numEmployees "72".
- Q17019665 revenue "1500000.0".
- Q17019665 website www.oxfordbiomedica.co.uk.
- Q17019665 type Organization.
- Q17019665 type Agent.
- Q17019665 type Company.
- Q17019665 type Organisation.
- Q17019665 type Agent.
- Q17019665 type SocialPerson.
- Q17019665 type Thing.
- Q17019665 type Q43229.
- Q17019665 comment "Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development and commercialisation of innovative gene-based medicines. It was established in 1995 as a spin out from Oxford University. The lead product is TroVax, a therapeutic cancer vaccine for multiple solid cancers, which is in Phase III development incollaboration with Sanofi-Aventis.".
- Q17019665 label "Oxford BioMedica".
- Q17019665 homepage www.oxfordbiomedica.co.uk.
- Q17019665 name "Oxford BioMedica plc".